CAH Stock Recent News
CAH LATEST HEADLINES
The U.S. Food and Drug Administration on Thursday sent a warning letter to Cardinal Health after an inspection of its facility in Illinois showed that the company was marketing unapproved devices.
Are we headed for a repeat of 2022's brutal selloff? While no one can predict the future with certainty, current market trends are raising some ominous red flags.
Cardinal Health (CAH) closed the most recent trading day at $103.37, moving +0.53% from the previous trading session.
Recently, Zacks.com users have been paying close attention to Cardinal (CAH). This makes it worthwhile to examine what the stock has in store.
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
The pharmaceutical distribution contract with OptumRx will expire in June.
Cardinal Health Inc. ‘s stock CAH, +2.07% fell 3.6% early Monday, after the pharmaceuticals distributor and medical lab products maker said its contracts with pharmacy benefits manager OptumRx will expire at the end of June and will not be renewed. The Dublin, Ohio-based company said it still expects 2024 EPS of $7.20 to $7.35 despite the end of the contract, which generated 16% of its revenue in fiscal 2023.
Cardinal Health is overvalued, with a dividend yield lower than its historical average and a high P/E ratio. Growth projections for the Company are moderate, with a projected growth rate of 7.8% for the next 5 years. Return projections using the discounted dividend model suggest that CAH is still overvalued, with a fair price of around $79 compared to its current price of $106.
In the latest trading session, Cardinal Health (CAH) closed at $107.03, marking a +1.84% move from the previous day.
CPI, the Consumer Price Index, is a metric used to gauge the rate of inflation and deflation. It's released by the Bureau of Labor Statistics (BLS) and reports the monthly fluctuations in consumer goods and services prices.